Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVR NYSE:CATX NASDAQ:LUCD NASDAQ:OM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVRAnteris Technologies Global$4.11+2.2%$3.57$2.34▼$8.79$144.97MN/A88,597 shs132,590 shsCATXPerspective Therapeutics$3.32-1.2%$3.76$1.60▼$16.31$246.55M1.17925,415 shs533,606 shsLUCDLucid Diagnostics$1.28+1.6%$1.09$0.73▼$1.80$136.68M1.24741,799 shs865,872 shsOMOutset Medical$13.74-1.2%$16.54$5.85▼$25.35$247.13M2.13277,528 shs128,574 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVRAnteris Technologies Global+2.24%+8.73%+33.88%-13.29%+410,999,900.00%CATXPerspective Therapeutics-1.19%-7.78%-9.78%+6.07%-78.99%LUCDLucid Diagnostics+1.59%+8.47%+28.00%+4.92%+59.92%OMOutset Medical-1.22%-2.55%-8.64%-28.88%+72.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVRAnteris Technologies Global1.915 of 5 stars3.50.00.00.02.60.00.6CATXPerspective Therapeutics1.9598 of 5 stars3.62.00.00.02.50.80.0LUCDLucid Diagnostics2.8892 of 5 stars3.51.00.00.03.23.30.6OMOutset Medical1.6086 of 5 stars3.51.00.00.03.20.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVRAnteris Technologies Global 3.00Buy$16.50301.46% UpsideCATXPerspective Therapeutics 3.18Buy$12.56278.18% UpsideLUCDLucid Diagnostics 3.00Buy$3.55177.34% UpsideOMOutset Medical 3.00Buy$24.6779.52% UpsideCurrent Analyst Ratings BreakdownLatest OM, CATX, LUCD, and AVR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025OMOutset MedicalRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$22.008/13/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.008/7/2025OMOutset MedicalRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$21.00 ➝ $22.007/16/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.007/14/2025OMOutset MedicalBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$37.007/12/2025CATXPerspective TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.006/6/2025LUCDLucid DiagnosticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.50 ➝ $7.756/3/2025CATXPerspective TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVRAnteris Technologies Global$2.70M54.89N/AN/A$0.67 per share6.13CATXPerspective TherapeuticsN/AN/AN/AN/A$2.67 per shareN/ALUCDLucid Diagnostics$4.35M31.92N/AN/A($0.43) per share-2.98OMOutset Medical$113.69M2.15N/AN/A$8.50 per share1.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVRAnteris Technologies Global-$76.29MN/A0.00N/AN/AN/AN/AN/A11/10/2025 (Estimated)CATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%11/11/2025 (Estimated)LUCDLucid Diagnostics-$45.53M-$1.19N/AN/AN/A-1,476.35%N/A-120.43%11/12/2025 (Estimated)OMOutset Medical-$127.98M-$20.29N/A∞N/A-82.06%-97.17%-32.84%11/5/2025 (Estimated)Latest OM, CATX, LUCD, and AVR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025 TUAVRAnteris Technologies Global-$0.5333-$0.58-$0.0467-$0.58$0.58 million$0.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVRAnteris Technologies GlobalN/AN/AN/AN/AN/ACATXPerspective TherapeuticsN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/AOMOutset MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVRAnteris Technologies GlobalN/A2.412.38CATXPerspective TherapeuticsN/A9.609.60LUCDLucid DiagnosticsN/A1.151.13OMOutset Medical0.637.476.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVRAnteris Technologies GlobalN/ACATXPerspective Therapeutics54.66%LUCDLucid Diagnostics74.01%OMOutset MedicalN/AInsider OwnershipCompanyInsider OwnershipAVRAnteris Technologies Global4.00%CATXPerspective Therapeutics3.72%LUCDLucid Diagnostics6.80%OMOutset Medical2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVRAnteris Technologies Global13836.06 million34.62 millionN/ACATXPerspective Therapeutics7074.26 million65.21 millionOptionableLUCDLucid Diagnostics70108.48 million101.10 millionNo DataOMOutset Medical52017.77 million17.34 millionNot OptionableOM, CATX, LUCD, and AVR HeadlinesRecent News About These CompaniesGMT Capital Corp Cuts Stake in Outset Medical, Inc. $OMSeptember 1 at 6:00 AM | marketbeat.comT. Rowe Price Investment Management Inc. Makes New $17.73 Million Investment in Outset Medical, Inc. $OMAugust 27, 2025 | marketbeat.comOutset Medical (NASDAQ:OM) Given Sector Perform Rating at Royal Bank Of CanadaAugust 21, 2025 | marketbeat.comOutset Medical to Present at the 23rd Annual Morgan Stanley Global Healthcare ConferenceAugust 20, 2025 | globenewswire.comOutset Medical, Inc. $OM Shares Sold by National Bank of Canada FIAugust 19, 2025 | marketbeat.comOutset Medical’s Earnings Call Highlights Strong GrowthAugust 15, 2025 | theglobeandmail.comOutset Medical (OM) Receives a Hold from OppenheimerAugust 15, 2025 | theglobeandmail.comOutset Medical Inc.August 15, 2025 | barrons.comAfter Plunging 26.8% in 4 Weeks, Here's Why the Trend Might Reverse for Outset Medical (OM)August 15, 2025 | zacks.comOutset Medical (NASDAQ:OM) Stock Price Expected to Rise, Royal Bank Of Canada Analyst SaysAugust 8, 2025 | marketbeat.comWhat To Expect From Outset Medical Inc (OM) Q2 2025 EarningsAugust 7, 2025 | finance.yahoo.comOutset Medical Reports Strong Q2 Growth and Raises GuidanceAugust 7, 2025 | msn.comOutset Medical, Inc. (OM) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comOutset Medical, Inc. (OM) Reports Q2 Loss, Beats Revenue EstimatesAugust 6, 2025 | zacks.comOutset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and UtilizationAugust 6, 2025 | globenewswire.comUncovering Potential: Outset Medical's Earnings PreviewAugust 5, 2025 | benzinga.comTD Asset Management Inc Acquires New Stake in Outset Medical, Inc. (NASDAQ:OM)August 5, 2025 | marketbeat.comOutset Medical Appoints Brittni McGill as Chief Nursing Officer to Enhance Dialysis Care InnovationJuly 30, 2025 | quiverquant.comQOutset Medical Names First Chief Nursing OfficerJuly 30, 2025 | globenewswire.comOutset Medical to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025July 16, 2025 | globenewswire.comWhy Outset Medical's Rock-Bottom Valuation Masks Explosive GrowthJuly 7, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 20253 AI Infrastructure Stocks Powering the Next Tech RevolutionBy Ryan Hasson | August 8, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025Can AI Defense Contracts Push Palantir Shares Higher?By Chris Markoch | August 19, 2025OM, CATX, LUCD, and AVR Company DescriptionsAnteris Technologies Global NASDAQ:AVR$4.11 +0.09 (+2.24%) As of 09/2/2025 04:00 PM EasternAnteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.Perspective Therapeutics NYSE:CATX$3.32 -0.04 (-1.19%) Closing price 09/2/2025 04:00 PM EasternExtended Trading$3.34 +0.02 (+0.63%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Lucid Diagnostics NASDAQ:LUCD$1.28 +0.02 (+1.59%) Closing price 09/2/2025 04:00 PM EasternExtended Trading$1.27 -0.01 (-0.39%) As of 09/2/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Outset Medical NASDAQ:OM$13.74 -0.17 (-1.22%) Closing price 09/2/2025 04:00 PM EasternExtended Trading$13.42 -0.33 (-2.37%) As of 09/2/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Tests $412 Support as Options Traders Turn Bullish Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers Amazon Faces Rare Downgrade—Is the Rally at Risk? What to Watch for From D-Wave Now That Earnings Are Done Alibaba Rallies on New AI Chip Design, Sending NVIDIA Stock Lower 3 High-Yield Stocks Just Supercharged Their Dividends Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
